Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The NIH website-transition announcement banner was removed; the page still displays a 403 Forbidden error.
    Difference
    1%
    Check dated 2026-11-07T13:22:14.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The site revision identifier changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-31T14:26:08.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    A banner announces updates and FAQs about NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology.
    Difference
    1%
    Check dated 2026-10-24T14:49:41.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 while the page continues to show a 403 Forbidden error.
    Difference
    0.3%
    Check dated 2026-10-17T14:39:02.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.3%
    Check dated 2026-10-10T14:36:10.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the expected study content and indicating the page is currently inaccessible.
    Difference
    20%
    Check dated 2026-09-19T19:12:26.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.